Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.

A轮融资由BioGeneration Ventures、Angelini Ventures和Kurma Partners联合领投，Epidarex Capital、Vesalius Biocapital Partners、ROM Utrecht Region、p53 Invest和Kerna Ventures参与投资。

Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies.

这笔融资将推动一种潜在的每日一次口服疗法的研发，该疗法旨在恢复遗传性出血性毛细血管扩张症（HHT）患者的血管稳定性；HHT是一种严重的遗传性出血性疾病，目前尚无获批的治疗方法。

periSCOPE platform supports pipeline expansion across vascular diseases associated with vascular instability.

periSCOPE平台支持在与血管不稳定性相关的血管疾病领域进行管线拓展。

NAARDEN, the Netherlands, Oct. 06, 2026 (GLOBE NEWSWIRE) --

荷兰纳尔登，2026年10月6日（环球电讯社）--

RougeTx,

RougeTx

a preclinical-stage biotechnology company developing first-in-class disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction, today announced its launch with a $58 million Series A financing. The round was co-led by founding investor BioGeneration Ventures (BGV) with Angelini Ventures, together with EIB (European Investment Bank) co-investment facility Aurea, and Kurma Partners, with further participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures..

一家处于临床前阶段的生物技术公司今日宣布正式启动运营，并完成5800万美元的A轮融资。该公司致力于开发首创的疾病修饰疗法，旨在通过靶向周细胞功能障碍来恢复血管完整性。本轮融资由创始投资方BioGeneration Ventures（BGV）与Angelini Ventures共同领投，欧洲投资银行（EIB）旗下的Aurea共投资基金以及Kurma Partners参与联合领投；Epidarex Capital、Vesalius Biocapital Partners、乌得勒支地区ROM、p53 Invest和Kerna Ventures也参与了跟投。

The financing will support RTX-001, RougeTx's lead program, as it advances toward first-in-human clinical development for hereditary hemorrhagic telangiectasia (HHT). HHT is the second most common inherited bleeding disorder. The disease is caused by abnormal blood vessel formation known as arteriovenous malformations (AVMs), which can lead to recurrent nose and gastrointestinal bleeding, iron deficiency, chronic anemia, and potentially serious complications affecting major organs.

此次融资将支持RougeTx的核心项目RTX-001，推动其向遗传性出血性毛细血管扩张症（HHT）的首次人体临床试验阶段迈进。HHT是第二常见的遗传性出血性疾病。该病由称为动静脉畸形（AVMs）的异常血管形成引起，可能导致反复鼻出血和胃肠道出血、缺铁、慢性贫血，以及可能影响主要器官的严重并发症。

There are currently no approved therapies for HHT, and patients rely largely on supportive care and off-label treatments..

目前尚无针对遗传性出血性毛细血管扩张症（HHT）的获批疗法，患者主要依赖支持性护理和超说明书用药治疗。

“RTX-001 is designed to stabilize fragile blood vessels by restoring pericyte attachment. The data we have generated for RTX-001 gives us a strong foundation as we move toward the clinic. This financing also allows us to explore where the same biology may impact other vascular diseases,”

“RTX-001 旨在通过恢复周细胞附着来稳定脆弱的血管。我们为 RTX-001 生成的数据为我们迈向临床应用奠定了坚实的基础。此次融资还使我们能够探索相同的生物学机制是否会对其他血管疾病产生影响。”

said Andrew Lightfoot, Chief Executive Officer at RougeTx.

RougeTx 首席执行官安德鲁·莱特富特表示。

Franck Lebrin, Co-Founder and Scientific Advisor at RougeTx, remarked:

RougeTx 联合创始人兼科学顾问 Franck Lebrin 表示：

“RougeTx represents the culmination of more than 20 years of research, initially at Inserm and over the past decade in my laboratory at Leiden University Medical Center. I am excited by the opportunity to bring a novel treatment to the HHT community.”

“RougeTx 代表了超过20年研究的结晶，最初在法国国家健康与医学研究院（Inserm）进行，过去十年则在莱顿大学医学中心我的实验室中继续开展。我对能够为遗传性出血性毛细血管扩张症（HHT）患者群体带来一种新型治疗手段感到兴奋。”

Sandra Glucksmann, Executive Chair at RougeTx, noted:

RougeTx 执行董事长桑德拉·格鲁克斯曼指出：

“For too long, people living with HHT have faced a serious, lifelong disease with no approved treatment options. RougeTx was founded with a commitment to this community and a belief that advances in vascular biology can finally make a meaningful difference for patients and families. We are grateful to our investors for their support and shared commitment to our mission.”.

“长期以来，遗传性出血性毛细血管扩张症（HHT）患者一直面临着一种严重且终身的疾病，却没有任何获批的治疗选择。RougeTx 的成立源于我们对这一社区的承诺，并坚信血管生物学的进展最终能够为患者和家庭带来实质性的改善。我们感谢投资者对我们的支持以及对我们使命的共同承诺。”

Through its periSCOPE platform, RougeTx is applying its deep understanding of vascular biology beyond HHT to identify new treatment opportunities in diseases driven by vascular instability. The platform is intended to support a pipeline of small-molecule therapies based on a common underlying biology..

RougeTx 通过其 periSCOPE 平台，将其对血管生物学的深刻理解从遗传性出血性毛细血管扩张症（HHT）拓展至其他领域，以识别由血管不稳定性驱动的疾病中的新治疗机会。该平台旨在支持基于共同潜在生物学机制的小分子疗法研发管线。

In connection with the financing, Edward van Wezel, Managing Partner at BGV; Regina Hodits, Managing Director at Angelini Ventures; Hadrien Bouchez, Partner at Kurma Partners; Elizabeth Roper, Managing Partner at Epidarex Capital; and Stéphane Verdood, Managing Partner at Vesalius Biocapital Partners, will join RougeTx's Board of Directors alongside existing directors..

作为此次融资的一部分，BGV 的管理合伙人 Edward van Wezel、Angelini Ventures 的董事总经理 Regina Hodits、Kurma Partners 的合伙人 Hadrien Bouchez、Epidarex Capital 的管理合伙人 Elizabeth Roper 以及 Vesalius Biocapital Partners 的管理合伙人 Stéphane Verdood 将加入 RougeTx 董事会，与现有董事共同履职。

For further information, contact:

如需更多信息，请联系：

RougeTx

RougeTx

info@rougetx.com

info@rougetx.com

Media Enquiries

媒体咨询

Optimum Strategic Communications

奥普蒂姆战略传播

Zoe Bolt, Eleanor Cooper, Katherine Bliss

佐伊·博尔特，埃莉诺·库珀，凯瑟琳·布利斯

+44 (0) 203 882 9621

+44 (0) 203 882 9621

rougetx@optimumcomms.com

rougetx@optimumcomms.com

About RougeTx

关于 RougeTx

RougeTx is a spin-off from Leiden University Medical Center (LUMC) and is developing first-in-class small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction. Pericytes regulate angiogenesis and support blood vessel integrity and function. Our aim is to move beyond current symptom management toward urgently needed disease-modifying treatments for vascular diseases..

RougeTx 是莱顿大学医学中心（LUMC）的衍生公司，正在开发首创的小分子疗法，以恢复由周细胞功能障碍驱动的疾病中的血管稳定性。周细胞调节血管生成并维持血管的完整性和功能。我们的目标是超越当前的症状管理，朝着迫切需要的、能够改变疾病进程的血管疾病治疗方向迈进。

Our lead program targets Hereditary Hemorrhagic Telangiectasia (HHT) along with additional indications related to vascular stability diseases. For more information, please visit:

我们的核心项目针对遗传性出血性毛细血管扩张症（HHT）以及与血管稳定性疾病相关的其他适应症。欲了解更多信息，请访问：

https://www.rougetx.com/

https://www.rougetx.com/

About BGV

关于 BGV

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 450 million investing in areas where true scientific innovations, unmet medical need, and the potential to demonstrate a significant proof of concept all converge.

BioGeneration Ventures（BGV）是一家风险投资公司，专注于欧洲早期的生物技术企业。该公司通过在医疗健康领域的创新投资，并提供打造世界级企业所需的专业知识，取得了显著的财务回报佳绩。BGV 管理的资产规模超过 4.5 亿欧元，其投资领域聚焦于真正的科学创新、未满足的医疗需求以及具备展示重大概念验证潜力的交汇点。

BGV works with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. For further information, please visit: .

BGV 与创始团队合作，推动科学成果成熟化并打造公司。本公司凭借自身经验，指导项目推进至临床试验阶段，最终实现成功的药物开发并为投资者创造价值。如需更多信息，请访问：。

https://biogenerationventures.com/en/

https://biogenerationventures.com/en/

About Angelini Ventures

关于 Angelini Ventures

Angelini Ventures is an international venture capital company and part of Angelini Industries, an Italian industrial group working in health, industrial technology and consumer goods. Angelini Ventures was formed in 2022 with planned investments of €375 million, about €150 million of which have already been allocated to startups developing innovative solutions and ideas in biotechnology, medtech and digital health.

Angelini Ventures 是一家国际风险投资公司，隶属于意大利工业集团 Angelini Industries，该集团业务涵盖健康、工业技术和消费品领域。Angelini Ventures 成立于 2022 年，计划投资总额为 3.75 亿欧元，其中约 1.5 亿欧元已分配给在生物技术、医疗科技和数字健康领域开发创新解决方案和理念的初创企业。

It invests in innovative companies in Europe and North America that can improve patients’ life expectancy and quality of life. The company is based in Rome and has a global team of 25 professionals working in nine cities (Rome, Milan, Turin, London, Singapore, Boston, Berlin, Dubai, Geneva, New York, Munich, Basel and Paris).

该公司投资于欧洲和北美能够改善患者预期寿命和生活质量的创新企业。公司总部位于罗马，拥有一支由25名专业人士组成的全球团队，在九个城市（罗马、米兰、都灵、伦敦、新加坡、波士顿、柏林、迪拜、日内瓦、纽约、慕尼黑、巴塞尔和巴黎）开展工作。

Angelini Ventures is part of Angelini Industries’ strategy to promote innovation by combining existing capabilities and new skills to identify, finance and implement solutions that innovate on traditional healthcare models..

Angelini Ventures 是 Angelini Industries 战略的一部分，旨在通过结合现有能力与新技能，识别、资助并实施能够革新传统医疗保健模式的解决方案，从而推动创新。

About Kurma Partners

关于库尔玛合伙人

Founded in Paris in 2009, Kurma Partners, an Eurazeo group company, has established itself as a benchmark player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from inception through to growth stages, covering the entire healthcare spectrum through its various dedicated franchises.

Kurma Partners 成立于2009年，总部位于巴黎，是 Eurazeo 集团旗下公司，已成为通过融资推动创新、构建未来医疗健康产业的中坚力量。Kurma 投资于从初创到成长期的企业，并通过其多个专业投资平台覆盖医疗健康领域的全产业链。

These have expanded alongside successive funds in early-stage biotechnology (Biofunds I, II, and III), early-stage digital health and diagnostics (Kurma Diagnostics and Kurma Diagnostics 2), and most recently, growth capital (Kurma Growth Opportunities Fund). The Kurma team consists of 25 professionals, including 10 partners, operating across two offices in Paris and Munich.

这些基金随着早期生物技术（Biofunds I、II 和 III）、早期数字健康与诊断（Kurma Diagnostics 和 Kurma Diagnostics 2）以及最近的增长资本（Kurma Growth Opportunities Fund）的连续推出而不断扩展。Kurma 团队由 25 名专业人士组成，其中包括 10 名合伙人，在巴黎和慕尼黑两个办公室开展业务。

They are deeply integrated into the European ecosystem and have woven a robust network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry players, and peer investors. With this final closing, Kurma Partners' total Assets Under Management (AUM) across all franchises reached €1 billion.

他们深度融入欧洲生态系统，并与享有盛誉的研究机构、医院、企业家、行业参与者及同行投资者建立了强大的国际联系网络。随着此次最终关闭，Kurma Partners 旗下所有业务板块的管理资产总额（AUM）达到10亿欧元。

Kurma Partners is part of the Eurazeo group. For further information, please visit: .

Kurma Partners 是 Eurazeo 集团的一部分。如需更多信息，请访问：。

https://www.kurmapartners.com/en

https://www.kurmapartners.com/en

About Epidarex Capital

关于 Epidarex Capital

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the UK and US. Epidarex's experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For further information, please visit: .

Epidarex Capital 是一家横跨大西洋的风险投资公司，致力于在英国和美国的新兴枢纽打造卓越的生命科学企业。Epidarex 拥有经验丰富的早期投资团队，与企业家及领先的研究机构合作，将世界级的科研成果转化为高度创新的产品，以满足全球医疗保健领域尚未满足的重大需求。如需更多信息，请访问：。

https://epidarex.com/

https://epidarex.com/

About Vesalius Biocapital Partners

关于维萨里生物资本合伙人

Vesalius is a specialist life sciences venture capital investor, investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007. Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health.

Vesalius 是一家专注于生命科学领域的风险投资机构，自2007年以来，一直投资于药物研发、医疗器械诊断以及电子健康领域的后期阶段公司。于2023年6月推出的 Vesalius Biocapital IV 基金，旨在投资欧洲药物研发和数字健康领域的首创类及同类最优的生命科学公司。

Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs. The team is based in Europe to explore investment opportunities and valuation potential for the portfolio.

其投资组合在药物研发与非药物研发投资之间实现了良好平衡，并致力于为由科学支撑的创新项目及富有雄心的创业者提供资本支持。该团队立足欧洲，旨在发掘投资组合中的投资机会与估值潜力。

Managing Partners include Guy Geldhof, Dr Jean-Christophe Renondin and Stéphane Verdood. For more information, please visit: .

管理合伙人包括 Guy Geldhof、Jean-Christophe Renondin 博士和 Stéphane Verdood。如需更多信息，请访问：。

https://vesaliusbiocapital.com/

https://vesaliusbiocapital.com/